Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Axonics stock

AXNX
US05465P1012
A2N7B2

Price

70.98
Today +/-
+0
Today %
+0 %

Axonics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Axonics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Axonics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Axonics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Axonics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Axonics Stock Price History

DateAxonics Price
11/14/202470.98 undefined
11/13/202470.48 undefined

Axonics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Axonics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Axonics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Axonics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Axonics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Axonics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Axonics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Axonics’s growth potential.

Axonics Revenue, EBIT and net profit per share

DateAxonics RevenueAxonics EBITAxonics Net Income
2029e1.05 B undefined0 undefined0 undefined
2028e890.89 M undefined152.08 M undefined128.77 M undefined
2027e765.76 M undefined102.36 M undefined98.79 M undefined
2026e649.97 M undefined69.52 M undefined73.94 M undefined
2025e550.73 M undefined32.89 M undefined44.57 M undefined
2024e459.25 M undefined-10,200 undefined14.4 M undefined
2023366.38 M undefined-4.71 M undefined-6.09 M undefined
2022273.7 M undefined-42.3 M undefined-59.7 M undefined
2021180.3 M undefined-67.4 M undefined-80.1 M undefined
2020111.5 M undefined-53.8 M undefined-54.9 M undefined
201913.8 M undefined-80.6 M undefined-79.9 M undefined
2018700,000 undefined-32.1 M undefined-32.5 M undefined
2017100,000 undefined-18.2 M undefined-18.1 M undefined
20160 undefined-17.5 M undefined-17.4 M undefined

Axonics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0000.010.110.180.270.370.460.550.650.770.891.05
----753.8562.1651.6734.0725.4119.8318.0017.8716.3418.09
---53.8560.3663.8972.1674.8659.6949.8242.2235.8230.7926.07
000767115197274000000
-17-18-32-79-54-80-59-6144473981280
-5.8877.78146.88-31.6548.15-26.25-89.83-333.33214.2965.9134.2530.61-
25.325.327.828.63743.146.749.08000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Axonics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Axonics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20162017201820192020202120222023
               
8.224.4157.5183.7241.2220.9357.2344.96
000.47.918.32944.857.24
00000000
01.53.715.763.164.955.879.94
0.513.74.55.46.47.39.28
8.726.9165.3211.8328321.2465.1491.42
1.21.52.87.213.4141333.26
00000000
00000000
0.70.50.40.30.2106.586.381.38
00000105.594.499.42
0.30.43.40.60.60.60.614.45
2.22.46.68.114.2226.6194.3228.5
10.929.3171.9219.9342.2547.8659.4719.92
               
45.462.2000000.01
000.240.360.520.80.971.03
-49.1-67.2-99.6-179.6-234.5-314.6-374.3-380.35
-1-0.4-0.4-0.4-0.4-6.6-25.1-15.87
00000000
-4-4.3143.3183287.4482.4570.1637.56
0.61.63.45.910.77.79.118.45
0.90.81.76.213.919.223.627.36
00000032.60
00000000
000.8021.1000
1.52.45.912.145.726.965.345.82
0.30.122.720.30000
0000019.216.410.7
0004.59.219.47.625.84
0.30.122.724.89.238.62436.54
1.82.528.636.954.965.589.382.36
-2.2-1.8171.9219.9342.3547.9659.4719.92
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Axonics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Axonics's financial health and stability.

Assets

Axonics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Axonics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Axonics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Axonics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
-17-18-32-79-54-80-59-6
0001191112
0000000-6
0-1-2-14-47-9-2-66
00318315886108
00011200
00000000
-17-18-31-83-83-473-2
0-1-1-1-2-2-2-3
0-1-60459-143-120-116
00-584612-140-118-113
00000000
002000-2600
1351571181532081344
134165110144170133-3
---12.00-7.00-9.00-11.00--7.00
00000000
-1616737270-2017-121
-17.63-19.21-32.6-84.79-86.68-49.570.97-5.57
00000000

Axonics stock margins

The Axonics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Axonics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Axonics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Axonics's sales revenue. A higher gross margin percentage indicates that the Axonics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Axonics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Axonics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Axonics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Axonics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Axonics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Axonics Margin History

Axonics Gross marginAxonics Profit marginAxonics EBIT marginAxonics Profit margin
2029e74.94 %0 %0 %
2028e74.94 %17.07 %14.45 %
2027e74.94 %13.37 %12.9 %
2026e74.94 %10.7 %11.38 %
2025e74.94 %5.97 %8.09 %
2024e74.94 %-0 %3.14 %
202374.94 %-1.29 %-1.66 %
202272.23 %-15.45 %-21.81 %
202164.17 %-37.38 %-44.43 %
202060.18 %-48.25 %-49.24 %
201952.9 %-584.06 %-578.99 %
201857.14 %-4,585.71 %-4,642.86 %
201774.94 %-18,200 %-18,100 %
201674.94 %0 %0 %

Axonics Stock Sales Revenue, EBIT, Earnings per Share

The Axonics earnings per share therefore indicates how much revenue Axonics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Axonics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Axonics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Axonics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Axonics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Axonics Revenue, EBIT and net profit per share

DateAxonics Sales per ShareAxonics EBIT per shareAxonics Earnings per Share
2029e20.56 undefined0 undefined0 undefined
2028e17.43 undefined0 undefined2.52 undefined
2027e14.98 undefined0 undefined1.93 undefined
2026e12.72 undefined0 undefined1.45 undefined
2025e10.78 undefined0 undefined0.87 undefined
2024e8.99 undefined0 undefined0.28 undefined
20237.46 undefined-0.1 undefined-0.12 undefined
20225.86 undefined-0.91 undefined-1.28 undefined
20214.18 undefined-1.56 undefined-1.86 undefined
20203.01 undefined-1.45 undefined-1.48 undefined
20190.48 undefined-2.82 undefined-2.79 undefined
20180.03 undefined-1.15 undefined-1.17 undefined
20170 undefined-0.72 undefined-0.72 undefined
20160 undefined-0.69 undefined-0.69 undefined

Axonics business model

Axonics Modulation Technologies Inc. is a medical device company that was founded in 2013 and is headquartered in Irvine, California. The company specializes in the development and marketing of innovative therapy devices for the treatment of bladder dysfunction and bowel diseases. Axonics is one of the most popular companies on Eulerpool.com.

Axonics SWOT Analysis

Strengths

Axonics Modulation Technologies Inc has several strengths that contribute to its competitive position in the market. These strengths include:

  • Advanced technology and innovative products
  • Strong intellectual property portfolio
  • Robust financial performance and healthy cash reserves
  • Strong brand reputation and customer loyalty
  • Qualified and experienced management team

Weaknesses

Despite its strengths, Axonics Modulation Technologies Inc also has weaknesses that can hinder its growth and competitiveness. These weaknesses include:

  • Relatively small market share compared to competitors
  • Limited geographic presence
  • Dependence on a few key suppliers
  • Higher production costs compared to some competitors

Opportunities

Axonics Modulation Technologies Inc can leverage the following opportunities to further expand its market presence and profitability:

  • Growing demand for advanced medical technologies
  • Expanding into untapped international markets
  • Developing strategic partnerships and collaborations
  • Capitalizing on demographic trends, such as an aging population

Threats

However, Axonics Modulation Technologies Inc faces certain threats that pose challenges to its business operations and performance. These threats include:

  • Intense competition from established players and new entrants
  • Rapidly changing regulatory landscape in the healthcare sector
  • Technological advancements by competitors
  • Economic downturns and volatility in financial markets

Axonics Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Axonics Revenue by Segment

Segmente202320222021
SNM net revenue291.81 M USD--
Bulkamid net revenue74.57 M USD--

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Axonics Revenue by Segment

Segmente202320222021
SNM net revenue-221.99 M USD-
Sacral Neuromodulation--157.6 M USD
Bulkamid net revenue-51.71 M USD-
Bulkamid--22.7 M USD

Axonics Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Axonics Revenue by Segment

DateInternational marketsUnited States
20203.99 M USD107.54 M USD
20195.44 M USD8.38 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Axonics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Axonics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Axonics shares outstanding

The number of shares was Axonics in 2024 — This indicates how many shares 49.081 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Axonics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Axonics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Axonics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Axonics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Axonics.

Axonics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240.14 0  (-100 %)2024 Q3
6/30/20240.13 0.13  (-0.99 %)2024 Q2
3/31/2024-0.09 -0.27  (-215.05 %)2024 Q1
12/31/20230.06 0.13  (118.86 %)2023 Q4
9/30/2023-0.06 0.08  (242.6 %)2023 Q3
6/30/2023-0.12 0.16  (238.05 %)2023 Q2
3/31/2023-0.29 -0.19  (35.18 %)2023 Q1
12/31/2022-0.25 0.01  (104.06 %)2022 Q4
9/30/2022-0.49 -0.34  (29.93 %)2022 Q3
6/30/2022-0.55 -0.47  (15.15 %)2022 Q2
1
2
3

Eulerpool ESG Scorecard© for the Axonics stock

Eulerpool World ESG Rating (EESG©)

36/ 100

🌱 Environment

39

👫 Social

46

🏛️ Governance

23

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees58
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Axonics shareholders

%
Name
Stocks
Change
Date
9.84257 % The Vanguard Group, Inc.5,030,539-5646/30/2024
7.34828 % BlackRock Institutional Trust Company, N.A.3,755,70579,7016/30/2024
4.12614 % Alpine Associates Management Inc.2,108,871294,1006/30/2024
3.99284 % Fidelity Investments Canada ULC2,040,739321,2396/30/2024
3.47259 % Soros Fund Management, L.L.C.1,774,8421,478,8876/30/2024
2.64569 % Westchester Capital Management, LLC1,352,210208,4376/30/2024
2.48808 % Norges Bank Investment Management (NBIM)1,271,656666,7256/30/2024
2.46496 % Mackenzie Investments1,259,840-7,5356/30/2024
2.38808 % Kryger Capital Limited1,220,547275,0466/30/2024
2.36931 % State Street Global Advisors (US)1,210,95217,0156/30/2024
1
2
3
4
5
...
10

Axonics Executives and Management Board

Mr. Raymond Cohen

(64)
Axonics Chief Executive Officer, Director (since 2015)
Compensation 5.33 M

Mr. Rinda Sama

(44)
Axonics Chief Operating Officer
Compensation 2.68 M

Mr. John Woock

(40)
Axonics Executive Vice President, Chief Marketing and Strategy Officer
Compensation 2.68 M

Mr. Alfred Ford

(52)
Axonics Chief Commercial Officer
Compensation 2.17 M

Mr. Danny Dearen

(60)
Axonics President, Chief Financial Officer (since 2019)
Compensation 1.82 M
1
2
3

Most common questions regarding Axonics

What values and corporate philosophy does Axonics represent?

Axonics Modulation Technologies Inc represents a strong commitment to providing innovative medical solutions for patients with urinary and bowel dysfunction. The company's corporate philosophy revolves around advancing patient care through technological advancements. Axonics Modulation Technologies Inc focuses on developing and commercializing innovative products that aim to improve the quality of life for individuals suffering from functional disorders. With a comprehensive portfolio of neurostimulation systems, Axonics Modulation Technologies Inc aims to offer effective and sustainable treatment options. This commitment to patient-centered care and technological innovation sets Axonics Modulation Technologies Inc apart in the healthcare industry.

In which countries and regions is Axonics primarily present?

Axonics Modulation Technologies Inc is primarily present in multiple countries and regions. The company has a global presence, with operations and partnerships in various parts of the world. Some key markets where Axonics Modulation Technologies Inc is active include the United States, Europe, Canada, Australia, and certain countries in the Asia Pacific region. With its innovative medical devices and solutions, Axonics Modulation Technologies Inc is committed to improving the lives of patients worldwide.

What significant milestones has the company Axonics achieved?

Axonics Modulation Technologies Inc has achieved several significant milestones. Firstly, the company received FDA approval for its rechargeable sacral neuromodulation (SNM) system, which provides therapy for overactive bladder and urinary retention. Secondly, Axonics Modulation Technologies Inc successfully completed its initial public offering (IPO) in November 2018, raising approximately $120 million. Additionally, the company announced positive clinical trial results demonstrating the safety and effectiveness of its SNM system. Furthermore, Axonics Modulation Technologies Inc expanded its global presence by entering into multiple distribution agreements in Europe and other international markets. These milestones highlight the company's success in product development, market expansion, and regulatory accomplishments.

What is the history and background of the company Axonics?

Axonics Modulation Technologies Inc is a prominent medical technology company specializing in the development and commercialization of innovative bladder and bowel management solutions. Founded in 2013, Axonics utilizes advanced neuromodulation technology to provide patients with long-lasting and effective treatment options for overactive bladder and fecal incontinence. The company's cutting-edge products, such as the Axonics r-SNM System, offer safe and durable solutions for patients seeking relief from these debilitating conditions. Axonics Modulation Technologies Inc has quickly gained recognition in the medical field for its dedication to improving the quality of life for individuals suffering from bladder and bowel dysfunction.

Who are the main competitors of Axonics in the market?

The main competitors of Axonics Modulation Technologies Inc in the market include Medtronic, Boston Scientific, and Nevro Corp.

In which industries is Axonics primarily active?

Axonics Modulation Technologies Inc is primarily active in the medical device industry. They specialize in the development and commercialization of innovative products for the treatment of urinary and bowel dysfunction. Axonics Modulation Technologies Inc prides itself on providing advanced and minimally invasive solutions using neurostimulation technology. With a focus on improving patients' quality of life, Axonics Modulation Technologies Inc sets itself apart in meeting the growing demand for effective and long-lasting treatment options. As a prominent player in the medical device sector, Axonics Modulation Technologies Inc continues to drive advancements and deliver exceptional solutions for patients in need.

What is the business model of Axonics?

Axonics Modulation Technologies Inc's business model revolves around developing and commercializing innovative medical devices for the treatment of various urinary and bowel dysfunctions. The company primarily focuses on the design, manufacturing, and marketing of its implantable neuromodulation devices, which are targeted towards patients suffering from overactive bladder, urinary retention, and fecal incontinence. By providing technologically advanced products, Axonics aims to improve the quality of life for individuals affected by these conditions. The company's dedication to addressing unmet medical needs and delivering clinically proven solutions has established Axonics Modulation Technologies Inc as a leader in the field.

What is the P/E ratio of Axonics 2025?

The Axonics P/E ratio is 78.16.

What is the P/S ratio of Axonics 2025?

The Axonics P/S ratio is 6.33.

What is the Quality Investing of Axonics?

The Quality Investing for Axonics is 2/10.

What is the revenue of Axonics 2025?

The expected Axonics revenue is 550.73 M USD.

How high is the profit of Axonics 2025?

The expected Axonics profit is 44.57 M USD.

What is the business model of Axonics

Axonics Modulation Technologies Inc is a US company that develops and manufactures medical technology for the treatment of chronic diseases of the nervous system. Axonics' business model is to provide high-quality, innovative products for patients suffering from incontinence and other disorders of the peripheral nervous system. Axonics specializes in the development and marketing of implanted devices for electrical stimulation of the nervous system. These devices, known as the Axonics Neuromodulation System, aim to stimulate nerve signals and improve the functioning of the nervous system. The Axonics Neuromodulation System includes a neurostimulating electrode placed directly on the target nerve, and a small battery that is implanted near the electrode implant. Using programmer devices programmed by doctors, patients can select different therapy programs to achieve the best results. The Axonics Neuromodulation System offers an effective alternative to medication for the treatment of chronic diseases of the peripheral nervous system. It can significantly improve quality of life and reduce symptoms, particularly for patients who do not respond to medication or are affected by its side effects. In addition to developing neurostimulation devices, Axonics is also involved in research and development of technologies to improve the effectiveness of neuromodulation treatments. This includes continuous monitoring programs of the power supply of the Axonics Neuromodulation System to ensure that the device is always adequately powered. Furthermore, Axonics is engaged in the development of imaging and diagnostic procedures to improve the diagnosis of peripheral nervous system diseases. This includes imaging technologies that allow better visualization of nerves and the brain, as well as procedures to measure the activity of the nervous system. Overall, Axonics' business model targets individuals with chronic diseases of the peripheral nervous system who are seeking effective and safe methods to improve their quality of life. With its innovative products and technologies, Axonics has the potential to revolutionize the treatment of incontinence and other peripheral nervous system disorders and help millions of people worldwide.

What is the Axonics dividend?

Axonics pays a dividend of 0 USD distributed over payouts per year.

How often does Axonics pay dividends?

The dividend cannot currently be calculated for Axonics or the company does not pay out a dividend.

What is the Axonics ISIN?

The ISIN of Axonics is US05465P1012.

What is the Axonics WKN?

The WKN of Axonics is A2N7B2.

What is the Axonics ticker?

The ticker of Axonics is AXNX.

How much dividend does Axonics pay?

Over the past 12 months, Axonics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Axonics is expected to pay a dividend of 0 USD.

What is the dividend yield of Axonics?

The current dividend yield of Axonics is .

When does Axonics pay dividends?

Axonics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Axonics?

Axonics paid dividends every year for the past 0 years.

What is the dividend of Axonics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Axonics located?

Axonics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Axonics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Axonics from 1/2/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/2/2025.

When did Axonics pay the last dividend?

The last dividend was paid out on 1/2/2025.

What was the dividend of Axonics in the year 2024?

In the year 2024, Axonics distributed 0 USD as dividends.

In which currency does Axonics pay out the dividend?

The dividends of Axonics are distributed in USD.

All fundamentals about Axonics

Our stock analysis for Axonics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Axonics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.